• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Research and Markets: European Cystic Fibrosis Market 2015-2019 - Key Vendors are Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis & Vertex Pharmaceuticals

    Research and Markets: European Cystic Fibrosis Market 2015-2019 - Key Vendors are Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis & Vertex Pharmaceuticals

  2. Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

    Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

  3. UPDATE: Biotech stocks on pace to snap 8-day win streak as warnings abound

    UPDATE: Biotech stocks on pace to snap 8-day win streak as warnings abound

  4. UPDATE: Chesapeake shares rise after capex budget trimmed

    UPDATE: Chesapeake shares rise after capex budget trimmed

  5. ESSA Pharma Inc. Announces Appointment of New Director

    ESSA Pharma Inc. Announces Appointment of New Director

  6. Research and Markets: Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

    Research and Markets: Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

  7. Five Consensus Views that Could Prove Wrong in 2015

    Options on this firm's blockbuster cost a little but pay off big.

  8. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...

  9. A Favorable Prognosis for This Pharma Stock

    Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.

  10. How Did Facebook End Up in the S&P 500?

    We dive into the process for adding companies and booting them from the iconic index.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.